{"id":"higher-dose-venlafaxine","safety":{"commonSideEffects":[{"rate":"30-40","effect":"Nausea"},{"rate":"25-35","effect":"Headache"},{"rate":"15-20","effect":"Dizziness"},{"rate":"15-20","effect":"Insomnia"},{"rate":"10-15","effect":"Somnolence"},{"rate":"10-15","effect":"Sexual dysfunction"},{"rate":"5-10","effect":"Hypertension"},{"rate":"10-15","effect":"Sweating"}]},"_chembl":{"chemblId":"CHEMBL1201066","moleculeType":"Small molecule","molecularWeight":"313.87"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Venlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) that blocks the reuptake transporters for both serotonin and norepinephrine, thereby prolonging their action at neuronal synapses. At higher doses, it also exhibits weak dopamine reuptake inhibition. This mechanism is used to treat depression and anxiety disorders by restoring neurotransmitter balance.","oneSentence":"Higher-dose venlafaxine inhibits the reuptake of serotonin and norepinephrine in the central nervous system, increasing their synaptic availability.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:22:24.401Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Major depressive disorder"},{"name":"Generalized anxiety disorder"},{"name":"Social anxiety disorder"},{"name":"Panic disorder"}]},"trialDetails":[{"nctId":"NCT06965569","phase":"PHASE1","title":"Multiple Ascending Dose Phase 1 Study of ALA-3000","status":"COMPLETED","sponsor":"Alar Pharmaceuticals Inc.","startDate":"2025-04-21","conditions":"Treatment Resistant Depression","enrollment":37},{"nctId":"NCT04539951","phase":"PHASE2","title":"Pragmatic Trial of Obsessive-compulsive Disorder","status":"RECRUITING","sponsor":"Shanghai Mental Health Center","startDate":"2020-09-22","conditions":"Obsessive-Compulsive Disorder","enrollment":1600},{"nctId":"NCT00854100","phase":"PHASE2","title":"Safety and Efficacy of Cariprazine As Adjunctive Therapy In Major Depressive Disorder","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2009-06-30","conditions":"Major Depressive Disorder","enrollment":231},{"nctId":"NCT01124188","phase":"PHASE4","title":"ADAPT: Addressing Depression and Pain Together","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2010-05","conditions":"Depression, Back Pain","enrollment":263},{"nctId":"NCT02237937","phase":"PHASE4","title":"Optimizing Antidepressant Treatment by Genotype-dependent Adjustment of Medication According to the ABCB1 Gene","status":"UNKNOWN","sponsor":"HolsboerMaschmeyer NeuroChemie GmbH","startDate":"2011-09","conditions":"Major Depression","enrollment":80},{"nctId":"NCT00074815","phase":"PHASE3","title":"Treatment of Obsessive Compulsive Disorder in Children","status":"COMPLETED","sponsor":"Duke University","startDate":"2003-09","conditions":"Obsessive-Compulsive Disorder","enrollment":124},{"nctId":"NCT00045916","phase":"PHASE4","title":"Optimizing Electroconvulsive Therapy for Depression","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2001-02","conditions":"Depression, Depressive Disorder, Bipolar Disorder","enrollment":340}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":23,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Effexor"],"phase":"marketed","status":"active","brandName":"Higher-dose venlafaxine","genericName":"Higher-dose venlafaxine","companyName":"University of Pittsburgh","companyId":"university-of-pittsburgh","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Higher-dose venlafaxine inhibits the reuptake of serotonin and norepinephrine in the central nervous system, increasing their synaptic availability. Used for Major depressive disorder, Generalized anxiety disorder, Social anxiety disorder.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}